Wolfram Dempke
Overview
Explore the profile of Wolfram Dempke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reuther S, Floegel K, Ceusters G, Albertini V, Baran J, Dempke W
Stem Cells Transl Med
. 2022 Apr;
11(6):604-612.
PMID: 35486383
Cord blood (CB) collected at birth has become a valuable stem cell source for hematopoietic stem cell transplantation (HSCT). However, the collection of umbilical cord blood always bears a risk...
2.
Sattler E, Syunyaeva Z, Reithmair M, Dempke W, Steinlein O
Eur J Cancer
. 2021 May;
151:168-174.
PMID: 34000505
Objective: Birt-Hogg-Dubé syndrome (BHDS) is an inherited tumour syndrome characterised by three major symptoms: lung cysts with spontaneous pneumothorax, fibrofolliculoma and renal cell cancer. The first family with this syndrome...
3.
Eisenmann S, Voigt W, Muller T, Dempke W
Anticancer Res
. 2010 Dec;
30(11):4471-6.
PMID: 21115895
Unlabelled: Cisplatin (CDDP) and oxaliplatin (OXA-P) are potential therapeutic drugs in the treatment of testicular cancer. However, the emergence of drug resistance has been documented not only in patients after...
4.
Dempke W, Zippel R
Med Klin (Munich)
. 2010 Oct;
105(10):711-5.
PMID: 20981590
The proto-oncogene src encodes a nonreceptor tyrosine kinase whose expression and activity are correlated with advanced malignancy and poor prognosis in a variety of human cancers. Nine additional enzymes with...
5.
Linke R, Dempke W
Onkologie
. 2007 Nov;
30(11):574-80.
PMID: 17992029
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line...
6.
Alimi K, Firusian N, Dempke W
Anticancer Res
. 2007 Aug;
27(4C):2997-3000.
PMID: 17695485
Background: The clinical outcome of refractory head and neck (H&N) cancer patients remains poor despite novel treatment strategies. In this pilot study the efficacy of intratumoral injection of 32-P chromic...
7.
Dempke W
Anticancer Res
. 2007 Jul;
27(4A):1745-57.
PMID: 17649769
The myelosuppressive toxicities of chemotherapy are one of the principle reasons for the overall failure of some agents to have a meaningful impact on responses and survival in cancer, and...
8.
Rennicke A, Voigt W, Mueller T, Fruehauf A, Schmoll H, Beyer C, et al.
Anticancer Res
. 2005 May;
25(2A):1147-55.
PMID: 15868958
Background: Oxaliplatin and cisplatin are widely used in cancer chemotherapy, however, their clinical efficiency is often limited by the development of resistance. Materials And Methods: We examined different mechanisms of...